Addressing the Lp(a) Hypothesis: Will Lowering Lp(a) Decrease the Risk of Cardiovascular Events?

Elevated plasma concentrations of lipoprotein(a) (Lp(a)) are an important risk factor for several cardiovascular diseases. However, to date, elevated Lp(a) levels have not been directly targeted by clinicians because Lp(a) levels are almost entirely genetically determined and are comparatively resistant to standard lipid-lowering therapies. This unmet medical need might soon be addressed with the advent of potent Lp(a)-lowering therapies.